United Parks & Resorts 株価情報 (NYSE: PRKS)

最新ニュース United Parks & Resorts (NYSE:PRKS) 株価情報

United Parks & Resorts

United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.

United Parks & Resorts Inc

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Monday.
Shares of Netflix, Inc. (NASDAQ: NFLX fell sharply in today's <a href="https://www.benzinga.com/general/education/25/05/45187710/peter-schiff-says-trumps-100-tariff-on-foreign-films-pointless-without-targeting-streamingwarns-netflix-subscribers-would-bear-cost">pre-market trading</a>.
Economist Peter Schiff criticized President Donald Trump‘s proposed 100% tariff on foreign-produced movies, questioning its implementation and suggesting that Netflix subscribers would ultimately bear the cost.
Netflix shares dipped 4.7% to $1,102.66 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>NetClass Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares tumbled 14.6% to $14.94 in pre-market trading.</li>
<li>ManpowerGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) shares dipped 10.4% to $39.71 in pre-market trading after gaining 4% on Friday.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) declined 9.8% to $2.29 in pre-market trading. ImmunityBio received a Refusal to File letter from the FDA for the supplemental biologics license application for ANKTIVA plus Bacillus Calmette-Guerin.</li>
<li>Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>) declined 9.4% to $10.98 in today's pre-market trading. Huntsman, last week, reported worse-than-expected first-quarter sales results.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) shares fell 7% to $10.10 in pre-market trading. On Friday, BWS Financial analyst Hamed Khorsand maintained Garrett Motion with a Buy and raised the price target from $12 to $14.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 5% to $9.80 in pre-market trading. USA Rare Earth recently announced a $75 million PIPE investment.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) fell 5% to $44.50 in pre-market trading after dipping 4% on Friday.</li>
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) dipped 4.8% to $13.39 in pre-market trading.</li>
<li>CNA Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) fell 2.6% to $47.11 in pre-market trading following downbeat quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

IBRX

NFLX

NTCL

UPXI

USAR

Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) with a Underperform and lowers the price target from $102 to $100.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Underperform on Brown & Brown, Lowers Price Target to $100

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Alan Lau initiated coverage on EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) with a Buy rating and announced a price target of $30.4. EHang shares closed at $18.82 on Friday. <a href="https://www.benzinga.com/quote/eh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Yun Kim initiated coverage on Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Buy rating and announced a price target of $140. Okta shares closed at $112.90 on Friday. <a href="https://www.benzinga.com/quote/OKTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Fawne Jiang initiated coverage on Marti Technologies, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MRT#AMEX">MRT</a>) with a Buy rating and announced a price target of $5. Marti Technologies shares closed at $3.02 on Friday. <a href="https://www.benzinga.com/quote/MRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann analyst Jeff Cohen initiated coverage on NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) with a Buy rating and announced a price target of $1.45. NeuroOne Medical Tech shares closed at $0.6255 on Friday. <a href="https://www.benzinga.com/quote/NMTC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Dylan Becker initiated coverage on Roper Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) with an Outperform rating. Roper Technologies shares closed at $566.04 on Friday. <a href="https://www.benzinga.com/quote/ROP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OKTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="558" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081627/image-38-1024x558.png" alt="" class="wp-image-901177" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081627/image-38-1024x558.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081627/image-38-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081627/image-38-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081627/image-38.png 1157w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Initiation

NMTC

OKTA

This Okta Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

WIIM

AXSM

Axsome Therapeutics shares are trading higher after the company announced a better-than-expected Q1 financial results.

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92
SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:&nbsp;JNJ) today announced new data from the TREMFYA&#xAE; (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025.&nbsp;

Johnson & Johnson Announces New Data From TREMFYA Phase 3 QUASAR LTE Study In Adults With Moderately-To-Severely Active Ulcerative Colitis

Contracts

OPTT

Ocean Power Technologies Awarded Contract To Provide Unmanned Surface Vehicles To A Defense Customer, Terms Not Disclosed

B of A Securities analyst Rafe Jadrosich initiates coverage on Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Buy rating and announces Price Target of $82.

B of A Securities Initiates Coverage On Meritage Homes with Buy Rating, Announces Price Target of $82

Howard Hughes Holdings shares are trading higher after the company announced an agreement with Pershing Square where it will make $900 million investment to acquire nine million newly issued shares.

- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production -
- Findings offer a more detailed understanding of WTX-921's anti-inflammatory impact on the immune landscape in the inflamed colon -
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced a poster presentation further characterizing its conditionally-activated IL-10 INDUKINE molecule, WTX-921, at IMMUNOLOGY2025, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Honolulu, Hawaii.
Werewolf's findings are summarized in a poster titled, "Development of WTX-921, A Conditionally Active IL-10 INDUKINETM Molecule for the Treatment of Inflammatory Bowel Disease" (Board #1230). The results build on <a href="https://www.globenewswire.com/Tracker?data=g3R9bl2jWOGQ6q_IEzlhTI_bJwQlKxmLrxnuucnG2cnuZZa-KTgfBGUoQfM82aBi0X7xdlI9i8WRdELXjhLEkuRKKyIJ5n6D_QfbkyoiVgehR0jyS9li4S78-4rmHENMMAhBCwszXKvjgywzqhJR70o2_kyEqJF0J-KNJgQDWpMqqqVsYOBukyCIW1UWr0vKaxiKebE9Tbjw7FB_LWeU9Bv1TahaiwvidIG_JNbqIBc=">initial data presented</a> at the 2024 AAI Annual Meeting, which revealed preliminary proof-of-concept for its IL-10 INDUKINE molecule as a potential prodrug for IBD treatment.
The data corroborate the preferential cleavage of inflammatory disease linkers by inflamed human IBD tissue samples and reduced colitis in a murine IBD model as previously observed. New results also highlight WTX-921's effective masking of IL-10 via its optimized IL-10 blocking domain, which prevents the peripheral off-tissue pharmacodynamic effects of IL-10. The CDC estimates that 7 million people worldwide had IBD in 2024, and while clinical studies in IBD involving IL-10 have shown promise, they are consistently hampered by dose-dependent adverse events.

Biotech

General

HOWL

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing Its IL-10 INDUKINE Molecule, WTX-921, For The Treatment Of Inflammatory Bowel Disease At AAI Annual Meeting

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

MARA

MARA Announces Bitcoin Production And Mining Operation Updates For April 2025; Energized Hash Rate Grew 5.5% To 57.3 EH/s; Increased BTC Holdings To 48,237 BTC

TREMFYA&#xAE; subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis&nbsp;
Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA&#xAE; in Crohn's disease&nbsp;&nbsp;
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA&#xAE; (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration (FDA)-approved intravenous (IV) induction regimen evaluated in this population, in the Phase 3 QUASAR study.1,2 TREMFYA&#xAE; is the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen. These findings are among 24 abstracts highlighting the Company's research being&nbsp;presented at Digestive Disease Week (DDW) 2025.&nbsp;

Johnson & Johnson Announces New Data From Phase 3 ASTRO Study Evaluating TREMFYA Subcutaneous Induction Therapy In Adults With Ulcerative Colitis

B of A Securities analyst Taylor Morrison initiates coverage on Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) with a Buy rating and announces Price Target of $70.

TMHC

B of A Securities Initiates Coverage On Taylor Morrison Home with Buy Rating, Announces Price Target of $70

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is down 10% over the past week but continues to attract bullish forecasts from traders, driven by its aggressive token burn rate and high <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">concentration in whale holdings</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001263</td>
<td>$7.4 billion</td>
<td>-2.7%</td>
<td>-9.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1705</td>
<td>$25.4 billion</td>
<td>-2.4%</td>
<td>-6.6%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.058064</td>
<td>$3.4 billion</td>
<td>-2%</td>
<td>-12.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: In an X post on May 4, crypto trader Javon Marks <a href="https://x.com/JavonTM1/status/1918774008436125894?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1918774008436125894%7Ctwgr%5E485fe5b8b8fae6ec6d87bab9d10ffac3eb58f508%7Ctwcon%5Es1_c10&amp;ref_url=https%3A%2F%2Feditorial.benzinga.com%2Fwp-admin%2Fpost.php%3Faction%3Deditpost%3D901027">reiterated</a> his bold call for SHIB to hit $0.000081, a nearly 500% gain from current levels.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We maintain our $0.000081 breakout target for <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> (Shiba Inu), projecting a nearly +500% uphill run to reach it&#8230; <a href="https://t.co/8OdILFYB5q">https://t.co/8OdILFYB5q</a> <a href="https://t.co/jTxSAGqiWA">pic.twitter.com/jTxSAGqiWA</a>
&mdash; JAVON&#x26a1;&#xFE0F;MARKS (@JavonTM1) <a href="https://twitter.com/JavonTM1/status/1918774008436125894?ref_src=twsrc%5Etfw">May 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Illusion X, <a href="https://x.com/illusionXcrypto/status/1919288659557196190">called</a> SHIB his "next big pick" for this cycle, projecting a 10x–15x move and urging accumulation.
Statistics: Shibburn data shows SHIB&#8217;s 24-hour burn rate jumping by 278.4%, with 2.2 million tokens incinerated in a single transaction just hours ago. 
The total weekly burn now stands at 313.95 million SHIB, a sign of consistent deflationary pressure that could boost price over time.
IntoTheBlock data shows Shiba Inu large transaction volume expanded by 8.9% while daily active addresses narrowed by 12.6% in a single day. 
Transactions greater than $100,000 increased from 38 to 43. SHIB whales still control 74% of the supply, underscoring continued long-term conviction among big holders.
Shiba Inu's Layer-2 network Shibarium has seen volatile usage, with daily transactions now at 3 million, bouncing back after a sharp 2-million drop. However, it has yet to reclaim its previous high of 4 million transactions.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45185999/shiba-inus-shibarium-is-booming-heres-whats-driving-the-54-transaction-surge">Shiba Inu&#8217;s Shibarium Is Booming — Here&#8217;s What&#8217;s Driving the 54% Transaction Surge</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Shiba Inu Drops 10% In 7 Days: What Is Going On?

TGTX

TG Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.

In a recent interview, Tesla CEO and billionaire Elon Musk shared what he hopes will eventually become his legacy: helping civilization progress.
Alongside his ambitious objectives for Tesla, SpaceX, and Neuralink, Musk stressed a mounting priority: developing artificial intelligence that is "maximally truth-seeking," which he called essential for AI safety.
What Happened: Speaking <a href="https://www.youtube.com/watch?v=1HcTXA951Mw">to</a> Lara Trump on Fox News, Musk listed a series of projects currently in development, including unsupervised self-driving cars that will make manually driven cars seem like "a horse", "robot buddies" that will assist humans in all kinds of tasks, space travel to enable the establishment of a "a self-sustaining city on Mars", and brain-computer interfaces that will "enable people who are blind to see" and "enable somebody who has a severed spinal column to walk again".
But he also issued a stark warning about AI: "The most important thing for AI safety is maximally truth-seeking AI… and if we don't, it will be very dangerous."
See Also: <a href="https://www.benzinga.com/markets/25/05/45186089/melinda-french-gates-takes-aim-at-elon-musks-doge-cuts-highlights-importance-of-philanthropy-and-government">Melinda French Gates Takes Aim at Elon Musk&#8217;s DOGE Cuts, Highlights Importance of Philanthropy and Government</a>
Why It Matters: Musk's statements come amid a series of controversies across sectors where he plays a central role.
NASA is about to see a <a href="https://www.benzinga.com/markets/25/05/45189017/nasa-prepares-for-6-billion-budget-cut-amid-shift-towards-elon-musks-mars-focused-initiatives">budget cut of $6 billion</a>, in line with Musk's Mars-focused aspirations, with multiple projects in space science, Earth science, and mission support divisions under threat.
On the other hand, <a href="https://www.benzinga.com/general/space/25/05/45163320/as-elon-musks-spacex-adds-28-starlinks-research-flags-climate-impact-from-deorbiting-satellites">a new study</a> showed that emissions from dying satellites may cause serious environmental damage, just as SpaceX added 28 more Starlink satellites to its burgeoning megaconstellation.
Meanwhile, despite Musk's comments about AI safety, <a href="https://www.benzinga.com/tech/25/04/45100013/elon-musks-xai-supercomputer-powering-grok-faces-human-rights-violation-allegations-in-memphis-over-pollutio">xAI&nbsp;is under fire in Memphis</a> for deploying several methane gas turbines allegedly without permits at its&nbsp;supercomputer site.&nbsp;
Previously, Musk had pledged to <a href="https://www.benzinga.com/personal-finance/25/04/45055568/elon-musk-said-hed-give-6-billion-to-end-world-hunger-if-the-un-could-explain-how-they-did-but-he-didnt-give-them-a-dime">donate $6 Billion to end world hunger</a> if the World Food Programme could explain how the money would be spent, but did not make good on his promise despite being provided with a detailed plan.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45163408/doge-not-as-effective-as-id-like-says-elon-musk-calls-reform-really-difficult-like-changing-direction-of-a-fleet-of-supertankers">DOGE Not &#8216;As Effective As I&#8217;d Like,&#8217; Says Elon Musk, Calls Reform &#8216;Really Difficult,&#8217; Like &#8216;Changing Direction Of A Fleet Of Supertankers&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Elon Musk Wants His Legacy To Be Advancing Civilization, Says Without 'Truth-Seeking AI,' The Future Could Be 'Dangerous'

CBL &amp; Associates (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBL#NYSE">CBL</a>) reported quarterly earnings of $0.27 per share. This is a 2800 percent increase over losses of $(0.01) per share from the same period last year. The company reported $141.77 million in sales this quarter. This is a 9.80 percent increase over sales of $129.12 million the same period last year.

Earnings

CBL & Associates Q1 EPS $0.27 Up From $(0.01) YoY, Sales $141.77M Up From $129.12M YoY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Bose George downgraded the rating for Enact Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) from Outperform to Market Perform and maintained the price target of $39. Enact Holdings shares closed at $37.32 on Friday. <a href="https://www.benzinga.com/quote/ACT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert downgraded Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) from Buy to Hold. Plus Therapeutics shares closed at $0.6479 on Friday. <a href="https://www.benzinga.com/quote/PSTV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sheila Kahyaoglu downgraded the rating for Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Buy to Hold and cut the price target from $75 to $65. Parsons shares closed at $62.81 on Friday. <a href="https://www.benzinga.com/quote/PSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Matthew Prisco downgraded Onto Innovation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) from Overweight to Neutral and lowered the price target from $250 to $135. Onto Innovation shares closed at $127.10 on Friday. <a href="https://www.benzinga.com/quote/ONTI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Paul Golding downgraded the rating for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Outperform to Neutral and lowered the price target from $110 to $50. Block shares closed at $46.53 on Friday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying XYZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-1024x590.png" alt="" class="wp-image-901156" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Downgrades

ONTO

PSTV

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population&nbsp;
UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients)
Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced complete 36-week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The Company previously disclosed 24-week and interim 36-week <a href="https://www.globenewswire.com/Tracker?data=diu3sRtqDoO3CddHHbn-1YIMcDhLulLaVJA8eviOj85ECqub7JGw6zYVthGHGN5dU1NfRG3nappEVwgUj97ZXPYxytFSZ6q5Knqo6QgGuFhtRzj1FjjvaTh8dVzlXEJEj_k2kAiqsuewPlBupiFb-57G6-mr_p2ShyKM1ta3lIZRjAmQ1VxbkKhKbTKVEKyOlv3t-JxfijwSdE745k9nJO0ELZZwbQPIxWDCfKIidMg=">results</a>&nbsp;from its ASPIRE trial, demonstrating that UBX1325 was non-inferior to aflibercept at most time points through 36 weeks, except for the average of weeks 20 and 24, the primary endpoint.

UNITY Biotechnology Announces Complete 36-Week Results From Phase 2b ASPIRE Clinical Trial Of Intravitreal UBX1325 In Patients With Diabetic Macular Edema

Anthropic co‑founder Jack Clark says Silicon Valley can dial down the alarms over China's latest AI darling, DeepSeek.
What Happened: Speaking on a Hill &amp; Valley Forum panel hosted by Lightspeed's Ravi Mhatre, Clark <a href="https://youtu.be/SsEoFDc1DIg?t=728">called</a> the buzz "perhaps a bit overblown."
He said DeepSeek's new model looks "six to eight months behind" frontier systems from U.S. labs and is hobbled chiefly by scarce computing power.
Anthropic ran the same national‑security red‑team tests it uses internally and found the Chinese model "significantly behind" its own, Clark added. "Neither one is yet a concern for the Pentagon — they're simply symptoms of progress we should track," he said.
What To Know: DeepSeek, founded in 2023 in Hangzhou, grabbed headlines by open‑sourcing its <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43253190/deepseek-ai-etfs-take-a-hard-hit-amid">R1 reasoning model</a>, claiming it cost just $5.6 million to build — a figure Wedbush analyst Dan Ives <a href="https://www.benzinga.com/tech/25/01/43296460/dan-ives-says-chinese-startup-deepseeks-6-million-ai-development-assertion-is-likely-a-fictional-story">has called</a> "likely a fictional story" given the billions the West spends on comparable AI research.
See also: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45187951/on-semiconductor-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">ON Semiconductor Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Google DeepMind chief Demis Hassabis recently labeled R1 "the best work to come out of China," <a href="https://www.benzinga.com/markets/25/02/43586484/google-deepmind-ceo-calls-deepseek-ai-best-work-from-china-but-says-hype-is-overblown-theres-no-actual-new-scientific-advance">but stressed</a> it offered no real scientific breakthrough.
Even Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), whose GPUs power most large models, framed DeepSeek as proof that compliant hardware can <a href="https://www.benzinga.com/markets/equities/25/01/43256425/nvidia-says-deepseek-an-illustration-of-how-new-ai-models-can-be-created-while-being-export-control-compliant-amid-600-billion-market-value-plunge">still yield</a> competitive systems under U.S. export curbs. Yet performance gaps persist. Benzinga's <a href="https://www.benzinga.com/markets/asia/25/04/44932492/is-deepseeks-threat-overrated-a-comprehensive-analysis">technical review</a> last month concluded DeepSeek's threat to U.S. dominance is "still overrated."
Why It Matters: Technical benchmarks show DeepSeek still trails U.S. rivals, yet Mark Zuckerberg <a href="https://www.benzinga.com/tech/25/04/45090992/mark-zuckerberg-warns-of-serious-disadvantage-as-chinas-data-center-blitz-could-let-deepseek-leapfrog-us-ai-labs">refuses to ignore</a> China's push to build AI infrastructure. He told the Dwarkesh Podcast last week that the United States must streamline &#8220;the ability to build data centers and produce energy" or risk falling behind.
Chinese tech giants, meanwhile, keep pouring money into AI and slashing prices to grab market share. Late last month Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) rolled out its <a href="https://www.benzinga.com/markets/asia/25/04/45015548/baidu-goes-aggressive-chinas-in-ai-price-war-with-alibaba-deepseek">latest reasoning models</a>, Ernie 4.5 Turbo and Ernie X1 Turbo, while Alibaba Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and other peers unveiled <a href="https://www.benzinga.com/markets/emerging-markets/25/04/44796128/alibabas-quark-ai-surpasses-bytedances-doubao-with-150-million-monthly-users">developer‑friendly tools</a> that cost individuals just $1 a year. 
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/05/45188341/billionaire-mark-cuban-asks-if-small-businesses-be-ignored-after-trump-redirects-question-on-tariff-relief-for-little-businesses">Billionaire Mark Cuban Asks Should Small Businesses Be &#8216;Ignored&#8217; After Trump Redirects Question On Tariff Relief For &#8216;Little Businesses&#8217;</a>

BABA

BIDU

NVDA

Jeff Bezos‑Backed Anthropic Co‑Founder Says DeepSeek Hype Is 'A Bit Overblown,' Says R1 Trails US Labs By 'Six To Eight Months'

PTCT

PTC Therapeutics shares are trading lower. The company announced results from the Phase 2 PIVOT-HD study of PTC518 in Stage 2 and Stage 3 Huntington's disease patients.

Entertainment

Commodities

Press Releases

SeaWorld San Diego Debuts a One-of-a-Kind Wonder: Jewels of the Sea - The Ultimate Jellyfish Experience!

BABY SHARK MAKES A SPLASH AT SEAWORLD WITH EXCLUSIVE NEW LIVE CHARACTER EXPERIENCES AND ALL-NEW ANIMATED MUSIC VIDEO

SeaWorld Orlando Reaches Historic Milestone with 1,000th Manatee Rescue, Reinforcing Decades of Dedication to Animal Rescue, Rehabilitation and Return

Expedition Odyssey to Open May 1 at SeaWorld Orlando -- A First-of-Its-Kind Arctic Adventure

SeaWorld Parks Honor Military Appreciation Month with Free Park Admission to Active-Duty U.S. Military, Veterans and Their Families Through Annual Waves of Honor Program

Busch Gardens Parks Honor Military Appreciation Month with Free Park Admission to Active-Duty U.S. Military, Veterans and Their Families Through Annual Waves of Honor Program

United Parks & Resorts Kicks Off Nationwide Recruitment Week for 5,000 Summer Positions Coast to Coast Across All Parks

Busch Gardens Tampa Bay Launches Nearly $40 Million Park Transformation Under New Leadership

UNITED PARKS & RESORTS INC. ANNOUNCES FIRST QUARTER EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

The Legacy Continues: North America's Longest Inverted Family Coaster Opens at Busch Gardens Williamsburg on May 23 with the Return of the Big Bad Wolf

Comments

United Parks & Resorts

ニュース

最新ニュース United Parks & Resorts (NYSE:PRKS) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル